We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bayer Increases Ownership in PharmaNetics

By HospiMedica staff writers
Posted on 02 May 2001
Under a new agreement, Bayer Diagnostics (Tarrytown, NY, USA) has increased its equity ownership from 7% to 19.9% in PharmaNetics (Raleigh, NC, USA), paying US$17.4 million for newly issued shares of stock in the company.

In addition to this investment, the agreement expands the distribution agreement with PharmaNetics to include its Theranostic tests as part of Bayer Diagnostics' critical care product offering. More...
Bayer retains exclusive rights from PharmaNetics to sell and market Theranostic products outside the United States. The two companies will coordinate commercial activities to leverage each other's resources and expertise to best serve market needs. Also, they will collaborate with PharmaNetics' pharmaceutical partners to establish the value of Theranostic testing on a global basis.

Theranostics is a technology platform that allows doctors to determine patient therapy involving certain drugs that affect coagulation by providing rapid testing results on the biologic effects of the drugs. Depending on the application, the tests can act to screen for certain patient subsets, manage dosing, monitor therapy, or determine efficacy.

"We consider PharmaNetics a center of excellence for coagulation testing,” said Fran Tuttle, senior vice president of Bayer Diagnostics' Near Patient Testing segment. "We are excited to have the opportunity to participate in developing the Theranostic market with PharmaNetics.”





Related Links:
Bayer Diagnostics
PharmaNetics

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical System
Stealth AXiS
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.